Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

Core Insights - Foghorn Therapeutics Inc. is advancing its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs, showcasing significant progress in addressing challenging cancer targets [1][2] Selective ARID1B Degrader Program - The Selective ARID1B degrader targets a dependency found in up to 5% of solid tumors, including endometrial, gastric, gastroesophageal junction, bladder, and non-small cell lung cancer [3][5] - The program is advancing towards in vivo proof of concept expected in 2026, with recent data presented at the TPD and Induced Proximity Summit [4][5] Selective CBP Degrader Program - The Selective CBP degrader is on track for non-GLP toxicology studies in Q4 2025, with potential applications in EP300-mutant cancers and ER+ breast cancer, aiming for IND readiness in 2026 [5][8] - The program is designed to overcome challenges associated with dual inhibition of CBP and EP300, which have shown dose-limiting toxicities [7][9] Selective EP300 Degrader Program - The Selective EP300 degrader is focused on hematological malignancies such as multiple myeloma and diffuse large b-cell lymphoma, with IND-enabling studies planned for 2026 [9][10] - This program demonstrates encouraging anti-tumor efficacy and favorable tolerability in preclinical studies, differentiating itself from dual CBP/EP300 approaches [5][10] Company Overview - Foghorn Therapeutics is developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system, utilizing its Gene Traffic Control platform [11]